DSM says acqusition of formulator Fortitech has no Pharma implications

- Last updated on GMT

DSM says Fortitech deal has no Pharma implications
DSM says acquisition of food formulation technology firm wont impact its pharmaceutical business.

The Netherlands-based firm announced the $634m (€495m) tackeover of Fortitech earlier today, explaining the US firm’s range of formulation technologies will expand its offering to the food, beverage and nutritional.

In-Pharmatechnologist.com asked DSM if the deal, which is expected to close before the end of the year, had any implications for its pharmaceutical business given Firtitech’s formulation expertise.

However, according to spokesman Herman Betten the businesses are separate businesses.

Related topics: Ingredients

Related news

Show more